TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm

Abstract excerpt

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy with highly varied clinical presentation and patterns of progression.1,2 The multiple sites involved include the skin, bone marrow, lymph nodes, and peripheral blood 2 as well as the central nervous system.3 Diagnosis is most frequent in older males.4,5 The overall survival is affected with an increase in age, 4,6 presence of more than 3...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to CNS Lymphoma Diagnosis and Treatment
• Share to Cutaneous lymphoproliferative disorders research